Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTH NASDAQ:CERO NASDAQ:FLGC NASDAQ:VIVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.04-2.1%$0.04$0.01▼$0.17$1.91M-0.5124,032 shs16,280 shsCEROCERo Therapeutics$0.01-4.3%$0.02$0.01▼$8.90$496K0.13689,828 shs852,658 shsFLGCFlora Growth$1.87-2.6%$3.96$5.86▼$47.00$1.96M1.939,454 shs15,531 shsVIVSVivoSim Labs$0.58-5.6%$1.13$0.52▼$5.30$2.14M1.46.52 million shs3.75 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-2.06%+8.57%+15.15%-43.28%-75.80%CEROCERo Therapeutics-4.35%-26.67%+8.91%-63.33%-99.87%FLGCFlora Growth-2.60%-24.90%-59.70%-75.10%-92.50%VIVSVivoSim Labs-5.64%-34.13%-48.76%-64.04%-68.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$0.04-2.1%$0.04$0.01▼$0.17$1.91M-0.5124,032 shs16,280 shsCEROCERo Therapeutics$0.01-4.3%$0.02$0.01▼$8.90$496K0.13689,828 shs852,658 shsFLGCFlora Growth$1.87-2.6%$3.96$5.86▼$47.00$1.96M1.939,454 shs15,531 shsVIVSVivoSim Labs$0.58-5.6%$1.13$0.52▼$5.30$2.14M1.46.52 million shs3.75 million shs10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-2.06%+8.57%+15.15%-43.28%-75.80%CEROCERo Therapeutics-4.35%-26.67%+8.91%-63.33%-99.87%FLGCFlora Growth-2.60%-24.90%-59.70%-75.10%-92.50%VIVSVivoSim Labs-5.64%-34.13%-48.76%-64.04%-68.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path 0.00N/AN/AN/ACEROCERo Therapeutics 1.67Reduce$30.00272,627.27% UpsideFLGCFlora Growth 2.00Hold$30.001,504.28% UpsideVIVSVivoSim Labs 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest CERO, FLGC, BPTH, and VIVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026VIVSVivoSim Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/AFLGCFlora Growth$57.61M0.03N/AN/A$12.21 per share0.15VIVSVivoSim Labs$131K15.44N/AN/A$5.54 per share0.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%8/18/2026 (Estimated)CEROCERo Therapeutics-$8.30M-$71.01N/AN/AN/AN/AN/A-209.40%9/2/2026 (Estimated)FLGCFlora Growth-$15.91M-$32.49N/AN/AN/A-32.03%-64.02%-34.46%N/AVIVSVivoSim Labs-$2.48M-$5.36N/AN/AN/A-861.27%-15.51%-11.31%N/ALatest CERO, FLGC, BPTH, and VIVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/14/2026Q4 2026VIVSVivoSim LabsN/A-$2.21N/A-$2.21N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/AFLGCFlora GrowthN/AN/AN/AN/AN/AVIVSVivoSim LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A0.860.86CEROCERo TherapeuticsN/A0.560.56FLGCFlora GrowthN/A2.081.79VIVSVivoSim LabsN/A2.442.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%CEROCERo Therapeutics29.64%FLGCFlora Growth36.01%VIVSVivoSim Labs8.23%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path0.72%CEROCERo Therapeutics0.36%FLGCFlora Growth2.34%VIVSVivoSim Labs2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path1050.30 million5.73 millionNo DataCEROCERo Therapeutics845.11 million1.05 millionN/AFLGCFlora Growth2801.05 million1.02 millionNot OptionableVIVSVivoSim Labs203.49 million3.41 millionN/ACERO, FLGC, BPTH, and VIVS HeadlinesRecent News About These CompaniesVivoSim Labs Earnings Estimates, EPS & Revenue | NASDAQ:VIVSJuly 16 at 3:34 PM | benzinga.comWhy Vivosim Labs Shares Are Rocketing on Wednesday?July 16 at 9:09 AM | msn.comVivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional InvestorJuly 16 at 8:51 AM | financialpost.comFVivoSim Labs Announces $4.0 Million Private Placement with Institutional Investor and Warrant AmendmentJuly 16 at 8:51 AM | quiverquant.comQVivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional InvestorJuly 16 at 8:30 AM | globenewswire.comThree Biotechs Deliver Catalysts to WatchJuly 15 at 2:10 PM | markets.businessinsider.comVivoSim Labs Announces $5 Million Lilly Milestone Payment and FY2027 Revenue Growth GuidanceJuly 15 at 8:50 AM | quiverquant.comQVivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027July 15 at 8:05 AM | globenewswire.comVivoSim: Fiscal Q4 Earnings SnapshotJuly 14, 2026 | stamfordadvocate.comSVivoSim Labs Delays Annual SEC FilingJune 29, 2026 | tipranks.comVivoSim Skids on DataJune 29, 2026 | baystreet.caVivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology MeetingJune 29, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) SEC FilingsJune 29, 2026 | nasdaq.comVivoSim Labs, Inc. Common StockJune 26, 2026 | fxempire.comFVivoSim Labs Inc VIVSMay 17, 2026 | morningstar.comMVivoSim Labs IncMay 14, 2026 | cnn.comVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human ...April 30, 2026 | bakersfield.comBVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | financialpost.comFVivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal TestingApril 28, 2026 | globenewswire.comVivoSim Labs, Inc. Common Stock (VIVS) Real TimeApril 7, 2026 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCERO, FLGC, BPTH, and VIVS Company DescriptionsBio-Path NASDAQ:BPTH$0.04 0.00 (-2.06%) As of 07/17/2026 03:42 PM EasternBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.CERo Therapeutics NASDAQ:CERO$0.01 0.00 (-4.35%) As of 07/17/2026 03:57 PM EasternCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Flora Growth NASDAQ:FLGC$1.87 -0.05 (-2.60%) As of 07/16/2026Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.VivoSim Labs NASDAQ:VIVS$0.58 -0.03 (-5.64%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.58 0.00 (-0.52%) As of 07/17/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Has Broadcom Become Too Expensive for Its AI Story? 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
